정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2508 | Recruiting | A Phase 1, First-In-Human Study of the Investigational COVID-19 Vaccine SC-Ad6-1 in Healthy Volunteers | Covid19 | Biological: SC-Ad6-1 Biological: SC-Ad6-1 |
Phase 1 | Tetherex Pharmaceuticals Corporation | INDUSTRY | 100 | All | 18 Years ~ 60 Years | Tetherex Study Site, Brisbane, Queensland, Australia |
| 2507 | Recruiting | A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC | COVID-19 Vaccine | Biological: COVIVAC Biological: Phosphate-buffered saline |
Phase 2 | Institute of Vaccines and Medical Biologicals, Vietnam, National Institute of Hygiene and Epidemiology, Vietnam, Hanoi Medical University, Center for Disease Control of Thai Binh Province | INDUSTRY | 420 | All | 18 Years ~ 75 Years | Hanoi Medical University, Hanoi, Vietnam Thai Binh Center of Disease Control, Thai Binh, Vietnam |
| 2506 | Withdrawn | A Phase 1/2 Study to Assess Safety and Efficacy of BAT2020 in Hospitalized COVID-19 Patients | COVID-19 | Drug: BAT2020 | Phase 2 | Bio-Thera Solutions | INDUSTRY | 0 | All | 18 Years | Snake River Research, Idaho Falls, Idaho, United States |
| 2505 | Recruiting | A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19 | SARS-CoV-2 Infection | Biological: NGM621 Biological: Placebo |
Phase 2 | NGM Biopharmaceuticals, Inc | INDUSTRY | 48 | All | 18 Years ~ 70 Years | NGM Clinical Study Site, Brisbane, Australia |
| 2504 | Recruiting | A Phase 1/2 Study to Determine Safety and Immunogenicity of Two COVID 19 Vaccines VB10.2129 (RBD Candidate) and VB10.2210 (T Cell Candidate) Previously Vaccinated in Healthy Adult Volunteers | Infections | Biological: VB10.2129 Biological: VB10.2210 |
Phase 2 | Vaccibody AS | INDUSTRY | 160 | All | 18 Years ~ 60 Years | Haukeland University Hospital, Klinisk Forskningspost, Bergen, Norway Oslo University Hospital Ulleval Sykehus, Dept. Infection Diseases, Oslo, Norway |
| 2503 | Recruiting | A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children and Young Adults | SARS-CoV-2 Infection, COVID-19 | Biological: Biological/Vaccine: BNT162b2 10mcg Biological: BNT162b2 20mcg Biological: BNT162b2 30mcg Other: Placebo Biological: Biological/Vaccine: BNT162b2 3mcg |
Phase 3 | BioNTech SE, Pfizer | INDUSTRY | 11422 | All | 6 Months ~ 30 Years | University of Alabama at Birmingham - School of Medicine, Birmingham, Alabama, United States Kaiser Permanente Oakland, Oakland, California, United States Clinical & Translational Research Unit (CTRU) & Spectrum BioBank, Stanford University, Palo Alto, California, United States Center for Clinical Trials, LLC, Paramount, California, United States Center for Clinical Trials, Paramount, California, United States Peninsula Research Associates, Rolling Hills Estates, California, United States Kaiser Permanente Sacramento, Sacramento, California, United States Kaiser Permanente Santa Clara, Santa Clara, California, United States Bayview Research Group, LLC, Valley Village, California, United States Children's Hospital Colorado, Aurora, Colorado, United States Yale Center for Clinical Investigation, New Haven, Connecticut, United States Children's National Medical Center, Washington, District of Columbia, United States Acevedo Clinical Research Associates, Miami, Florida, United States Clinical Neuroscience Solutions, Orlando, Florida, United States Emory Children's Center Illness POD, Atlanta, Georgia, United States Emory University School of Medicine, Atlanta, Georgia, United States Atlanta Center for Medical Research, Atlanta, Georgia, United States Meridian Clinical Research, LLC, Macon, Georgia, United States Clinical Research Prime, Idaho Falls, Idaho, United States Solaris Clinical Research, Meridian, Idaho, United States Alliance for Multispecialty Research, LLC, Newton, Kansas, United States Alliance for Multispecialty Research, LLC, Wichita, Kansas, United States Kentucky Pediatric/ Adult Research, Bardstown, Kentucky, United States Novak Center for Children's Health, Louisville, Kentucky, United States Ochsner Clinic Foundation, New Orleans, Louisiana, United States Louisiana State University Health Sciences Shreveport, Shreveport, Louisiana, United States Center for Immunization Research Inpatient Unit, Baltimore, Maryland, United States Boston Medical Center, Boston, Massachusetts, United States Clinical Research Professionals, Chesterfield, Missouri, United States Children's Mercy Hospital, Kansas City, Missouri, United States Meridian Clinical Research, LLC, Hastings, Nebraska, United States Children's Hospital & Medical Center, Omaha, Nebraska, United States Children's Physician's Clinic, Spring Valley, Omaha, Nebraska, United States Rutgers University, New Brunswick, New Jersey, United States Meridian Clinical Research, LLC, Binghamton, New York, United States Advanced Specialty Care, Commack, New York, United States Clinical Research Center, East Setauket, New York, United States Rochester Clinical Research, Inc., Rochester, New York, United States University of Rochester Medical Center, Rochester, New York, United States Stony Brook University, Stony Brook, New York, United States SUNY Upstate Medical University, Syracuse, New York, United States Duke Vaccine and Trials Unit, Durham, North Carolina, United States Clinical Research Pickett Road, Durham, North Carolina, United States Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States Aventiv Research Inc., Columbus, Ohio, United States PriMed Clinical Research, Dayton, Ohio, United States Senders Pediatrics, South Euclid, Ohio, United States Allegheny Health and Wellness Pavilion, Erie, Pennsylvania, United States Velocity Clinical Research-Providence, Warwick, Rhode Island, United States St. Jude Children's Research Hospital, Memphis, Tennessee, United States Clinical Research Associates Inc, Nashville, Tennessee, United States ARC Clinical Research at Wilson Parke, Austin, Texas, United States Driscoll Children's Hospital, Corpus Christi, Texas, United States University of Texas Medical Branch-Sealy Institute for Vaccine Sciences Clinical Trials Program, Galveston, Texas, United States Van Tran Family Practice, Houston, Texas, United States Ventavia Research Group, LLC, Houston, Texas, United States Texas Children's Hospital - Clinical Research Center, Houston, Texas, United States West Houston Clinical Research Service, Houston, Texas, United States J. Lewis Research, Inc. / Foothill Family Clinic, Salt Lake City, Utah, United States J. Lewis Research, Inc. / Foothill Family Clinic South, Salt Lake City, Utah, United States Pediatric Associates of Charlottesville, PLC (Private Pediatric Practice), Charlottesville, Virginia, United States Pediatric Research of Charlottesville, LLC, Charlottesville, Virginia, United States Virginia Research Center, Midlothian, Virginia, United States Seattle Children's Hospital, Seattle, Washington, United States Tampere Vaccine Research Clinic, Tampere, Pirkanmaa, Finland Tampere university/ Oulu vaccine research clinic, Oulu, Pohjois-pohjanmaa, Finland Helsinki East Vaccine Research Clinic, Helsinki, Uusimaa, Finland Espoo Vaccine Research Clinic, Espoo, Finland Helsinki South Vaccine Research Clinic, Helsinki, Finland MeVac, Meilahti Vaccine Research Center, Helsinki, Finland Jarvenpaa Vaccine Research Center, Jarvenpaa, Finland Kokkola Vaccine Research Clinic, Kokkola, Finland Pori Vaccine Research Clinic, Pori, Finland Seinajoki Vaccine Research Clinic, Seinajoki, Finland Turku Vaccine Research Clinic, Turku, Finland IN VIVO Spolka z ograniczona odpowiedzialnoscia, Bydgoszcz, Poland Centrum Bada? Klinicznych Jagiello?skie Centrum Innowacji sp. z o.o., Krakow, Poland Osrodek Badan Klinicznych Appletreeclinics, Lodz, Poland GRAVITA Diagnostyka i Leczenie nieplodnosci, Lodz, Poland Rodzinne Centrum Medyczne LUBMED, Lubon, Poland Niepubliczny Zaklad Lecznictwa Ambulatoryjnego Michalkowice Jarosz i Partnerzy Spolka Lekarska, Siemianowice Slaskie, Poland Nasz Lekarz Przychodnie Medyczne, Torun, Poland Provita 001, Warszawa, Poland Hospital Clinico Universitario Santiago de Compostela, Santiago de Compostela, A Coruna, Spain EAP Centelles, Centelles, Barcelona, Spain Hospital Sant Joan de Deu, Esplugues De Llobregrat, Barcelona, Spain Hospital Universitari General de Catalunya, Sant Cugat del Valles, Barcelona, Spain Hospital Universitario HM Monteprincipe, Boadilla del Monte, Madrid, Spain Hospital de Antequera, Antequera, Malaga, Spain Grupo Pediatrico Uncibay, Malaga, Malaga, Spain Hospital Universitario 12 de Octubre, Madrid, Spain Hospital HM Puerta del Sur, Mostoles, Spain Instituto Hispalense de Pediatria, Sevilla, Spain |
| 2502 | Completed | A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19 | Corona Virus Infection | Drug: SAR443122 Drug: Placebo |
Phase 1 | Sanofi | INDUSTRY | 68 | All | 18 Years ~ 80 Years | Investigational Site Number 0320001, Caba, Argentina Investigational Site Number 0760003, Porto Alegre, Brazil Investigational Site Number 0760001, Sao Jose Do Rio Preto, Brazil Investigational Site Number 0760002, Sao Paulo, Brazil Investigational Site Number 1520001, Santiago, Chile Investigational Site Number 1520003, Santiago, Chile Investigational Site Number 1520002, Talca, Chile Investigational Site Number 4840001, Monterrey, Mexico Investigational Site Number 6430001, Moscow, Russian Federation Investigational Site Number 6430002, Moscow, Russian Federation |
